These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37159527)

  • 41. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibitors of sclerostin: emerging concepts.
    Drake MT; Farr JN
    Curr Opin Rheumatol; 2014 Jul; 26(4):447-52. PubMed ID: 24807403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
    Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
    Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
    Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
    Front Genet; 2021; 12():705505. PubMed ID: 34447412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton.
    Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Hong JM; Robling AG
    Aging Dis; 2022 Dec; 13(6):1891-1900. PubMed ID: 36465166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.
    McDonald MM; Morse A; Mikulec K; Peacock L; Yu N; Baldock PA; Birke O; Liu M; Ke HZ; Little DG
    J Orthop Res; 2012 Oct; 30(10):1541-8. PubMed ID: 22457198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
    Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
    Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sclerostin antibody increases trabecular bone and bone mechanical properties by increasing osteoblast activity damaged by whole-body irradiation in mice.
    Costa S; Fairfield H; Farrell M; Murphy CS; Soucy A; Vary C; Holdsworth G; Reagan MR
    Bone; 2021 Jun; 147():115918. PubMed ID: 33737193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X; Jee WS; Li X; Paszty C; Ke HZ
    Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect.
    Jawad MU; Fritton KE; Ma T; Ren PG; Goodman SB; Ke HZ; Babij P; Genovese MC
    J Orthop Res; 2013 Jan; 31(1):155-63. PubMed ID: 22887736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
    Alzahrani MM; Rauch F; Hamdy RC
    Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants.
    Yu SH; Hao J; Fretwurst T; Liu M; Kostenuik P; Giannobile WV; Jin Q
    Tissue Eng Part A; 2018 Nov; 24(21-22):1672-1679. PubMed ID: 29921173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
    Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
    Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.